Denali Therapeutics Inc (DNLI)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$5.50
Buy
$15.75
$1.45 (+11.80%)
Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
Prices updated at 03 Apr 2025, 09:05 BST
| Prices minimum 15 mins delay
|
Prices in USD
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| - | 129m | 27m | 336m | 49m | 108m | 331m | - | |
| - | - | - | - | - | - | - | - | |
| -90m | -46m | -213m | 63m | -296m | -341m | -197m | -502m | |
| - | -35.90 | -799.10 | 18.69 | -607.78 | -314.16 | -59.51 | - | |
| -88m | -36m | -198m | 71m | -291m | -326m | -145m | -423m | |
| -87m | -39m | -205m | 71m | -287m | -330m | -180m | -493m | |
| Sales, General and administrative | 16m | 32m | 46m | 60m | 79m | 90m | 103m | 105m |
| Interest expenses | - | - | - | - | - | - | - | - |
| Provision for income taxes | - | - | -351,000 | 823,000 | -575,000 | 21,000 | 30,000 | 68,000 |
| Operating expenses | 90m | 176m | 240m | 273m | 344m | 449m | 527m | 502m |
| Income before taxes | -88m | -36m | -198m | 72m | -291m | -326m | -145m | -423m |
| Net income available to common shareholders | -88m | -36m | -198m | 71m | -291m | -326m | -145m | -423m |
| -5.89 | -0.39 | -2.07 | 0.65 | -2.39 | -2.6 | -1.06 | -2.57 | |
| Net interest income | 2m | 10m | 15m | 9m | 5m | 15m | 52m | 65m |
| Advertising and promotion | - | - | - | - | - | - | - | - |
| Net investment income, net | - | - | - | - | - | - | - | - |
| Realised capital gains (losses), net | - | - | - | - | - | - | - | - |
| Total benefits, claims and expenses | - | - | - | - | - | - | - | - |
| Earnings per share (diluted) | -5.89 | -0.39 | -2.07 | 0.63 | -2.39 | -2.6 | -1.06 | -2.57 |
| Free cash flow per share | -1.6512 | -0.6856 | -0.2872 | -1.458 | 2.8963 | -2.0644 | -2.5546 | -2.4005 |
| Book value/share | 2.2078 | 4.8718 | 4.5555 | 7.3222 | 8.2781 | 5.967 | 8.0813 | 9.1422 |
| Debt equity ratio | - | - | 0.17439 | 0.055779 | 0.060849 | 0.050873 | 0.04363 | 0.029823 |
Balance sheet
Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Current assets | 410m | 481m | 430m | 1,496m | 897m | 1,372m | 1,064m | 864m |
| Current liabilities | 14m | 33m | 45m | 72m | 378m | 364m | 78m | 102m |
| Total capital | 466m | 547m | 395m | 1,151m | 962m | 1,042m | 1,031m | 1,230m |
| Total debt | - | - | 73m | 69m | 64m | 60m | 52m | 49m |
| Total equity | 466m | 547m | 395m | 1,151m | 962m | 1,042m | 1,031m | 1,230m |
| Total non current liabilities | - | - | - | - | - | - | - | - |
| Loans | - | - | - | - | - | - | - | - |
| Total assets | 487m | 662m | 553m | 1,604m | 1,404m | 1,460m | 1,154m | 1,374m |
| Total liabilities | - | - | - | - | - | - | - | - |
| Cash and cash equivalents | 218m | 77m | 79m | 507m | 293m | 218m | 127m | 175m |
| Common stock | 87m | 95m | 96m | 121m | 122m | 136m | 138m | 144m |
Cash flow
Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash at beginning of period | 40m | 219m | 79m | 81m | 509m | 295m | 220m | 129m |
| Cash dividends paid | - | - | - | - | - | - | - | - |
| -80m | 47m | -169m | 413m | -220m | -263m | -371m | -364m | |
| Investments (gains) losses | -41m | -287m | 148m | -623m | -22m | -141m | 249m | -89m |
| 218m | 79m | 81m | 509m | 295m | 220m | 129m | 177m | |
| Net income | - | - | - | - | - | - | - | - |
| -77m | 50m | -152m | 416m | -211m | -245m | -358m | -348m | |
| -3m | -3m | -18m | -3m | -8m | -18m | -13m | -16m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
